HI-Bio Positive Phase 2 Study of Felzartamab for Late Antibody-Mediated Rejection in Kidney Transplant

 

• 82% (n=9/11) of patients on felzartamab experienced resolution of antibody-mediated rejection per Banff criteria on biopsy at 24 weeks versus 20% (n=2/10) who received placebo, and patients treated with felzartamab showed reductions in disease-linked biomarkers and stabilization of eGFR
• 63% (n=7/11) of felzartamab-treated patients achieved microvascular inflammation (MVI) score of 0 and 100% (n=11/11) of felzartamab treated patients had an improvement in MVI score
• Results published in New England Journal of Medicine and presented at 61^st European Renal Association (ERA) Congress
• Results support advancement of felzartamab into late-stage development as a novel therapeutic approach in antibody-mediated rejection

https://www.biospace.com/article/releases/hi-bio-announces-positive-results-from-phase-2-study-of-felzartamab-for-late-antibody-mediated-rejection-in-kidney-transplant-recipients/